Investigating how adiponectin signaling affects heart health in diabetic patients
Dysregulated Adiponectin Transmembrane Signaling in Diabetic CoronaryVascular Injury and Heart Failure
['FUNDING_R01'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11011348
This study is looking at how a protein called adiponectin affects heart health in people with diabetes, especially after a heart attack, to find better ways to help them have healthier hearts.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11011348 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of adiponectin, a protein involved in regulating glucose levels and fatty acid breakdown, in the context of heart health for diabetic patients. It aims to explore how dysregulated signaling of adiponectin contributes to coronary vascular injury and heart failure, particularly after a myocardial infarction. By using animal models and examining human diabetic coronary endothelial cells, the study seeks to identify mechanisms that lead to increased cardiac dysfunction in diabetes. The ultimate goal is to develop integrative treatment strategies that could improve heart health outcomes for diabetic patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are diabetic patients who have experienced a myocardial infarction or are at risk of ischemic cardiomyopathy.
Not a fit: Patients without diabetes or those who have not experienced any cardiac events may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve heart function and reduce the risk of heart failure in diabetic patients.
How similar studies have performed: Previous studies have shown that adiponectin supplementation can protect the heart in animal models, but the effectiveness in humans remains to be fully established.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, YAJING — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: WANG, YAJING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.